Federal-Mogul U.S. Asbestos Personal Injury Trust

Founded in 1899, Federal-Mogul is a long-standing supplier in the automotive industry. Various asbestos claims against two acquired companies - Turner & Newall and Fel-Pro - in the late 1990s led to the company's Chapter 11 bankruptcy filing in 2001. The Federal-Mogul Asbestos Personal Injury Trust was established in 2007 with initial funding of $690 million to handle existing and future asbestos-related claims.

History of the Trust

In 1998, Federal-Mogul acquired Turner & Newall and Fel-Pro, companies known for producing gasket and automotive friction products such as brake pads, bearings, and seals that contained asbestos. Over time, the corporation faced numerous asbestos-related lawsuits. By 2001, it entered Chapter 11 bankruptcy, and after six years of proceedings, the Federal-Mogul Asbestos Personal Injury Trust Fund was created in 2007.

The Trust consists of two sub-funds: one solely for Turner & Newall claims and another covering all other asbestos-related liabilities.

Purpose of the Trust

The Trust was formed to provide fair, equitable, and consistent treatment for all asbestos claims - current and future - within the rules set forth by its Trust Distribution Procedures (TDP).

The Trust offers equitable treatment for all present and future Asbestos Trust Claims that meet established guidelines.

Why Choose Us for Your Asbestos Exposure Claim?

Free No-Obligation Review

We provide free no-obligation asbestos exposure case review

Contingency Representation

We work on a contingency basis, meaning there are no fees unless we collect for you

Expertise In Asbestos & Mesothelioma Lawsuits

We have experience winning claims against huge multi-national corporations

Eligibility and Claim Process

Claims are processed on a FIFO (first-in, first-out) basis. Claimants must demonstrate that their case fits one of eight asbestos-related disease levels. Seven of these levels require meeting presumptive Medical and Exposure Criteria.

Claimants may choose between two review options: Expedited Review or Individual Review.

Compensation and Payment Structure

Turner & Newall Claims

Scheduled Disease	Scheduled Value	Maximum Value
Mesothelioma (Level VIII)	$200,000	$600,000
Lung Cancer 1 (Level VII)	$42,500	$125,000
Lung Cancer 2 (Level VI)	None	$40,000
Other Cancer (Level V)	$14,750	$90,000
Severe Asbestosis (Level IV)	$42,500	$125,000
Asbestosis/Pleural Disease (Level III)	$12,700	$25,000
Asbestosis/Pleural Disease (Level II)	$5,700	$8,000
Other Asbestos Disease Cash Discount Payment (Level I)	$50	None

Scheduled Disease

Scheduled Value

Maximum Value

Mesothelioma (Level VIII)

$200,000

$600,000

Lung Cancer 1 (Level VII)

$42,500

$125,000

Lung Cancer 2 (Level VI)

None

$40,000

Other Cancer (Level V)

$14,750

$90,000

Severe Asbestosis (Level IV)

$42,500

$125,000

Asbestosis/Pleural Disease (Level III)

$12,700

$25,000

Asbestosis/Pleural Disease (Level II)

$5,700

$8,000

Other Asbestos Disease Cash Discount Payment (Level I)

$50

None

FMP Claims / Other Than Pneumo Claims

Scheduled Disease	Scheduled Value	Maximum Value
Mesothelioma (Level VIII)	$100,000	$300,000
Lung Cancer 1 (Level VII)	$21,250	$62,500
Lung Cancer 2 (Level VI)	None	$20,000
Other Cancer (Level V)	$7,375	$45,000
Severe Asbestosis (Level IV)	$21,250	$62,500
Asbestosis/Pleural Disease (Level III)	$4,000	$7,000
Asbestosis/Pleural Disease (Level II)	$2,000	$2,500
Other Asbestos Disease Cash Discount Payment (Level I)	$50	None

Scheduled Disease

Scheduled Value

Maximum Value

Mesothelioma (Level VIII)

$100,000

$300,000

Lung Cancer 1 (Level VII)

$21,250

$62,500

Lung Cancer 2 (Level VI)

None

$20,000

Other Cancer (Level V)

$7,375

$45,000

Severe Asbestosis (Level IV)

$21,250

$62,500

Asbestosis/Pleural Disease (Level III)

$4,000

$7,000

Asbestosis/Pleural Disease (Level II)

$2,000

$2,500

Other Asbestos Disease Cash Discount Payment (Level I)

$50

None

Conclusion

The Federal-Mogul U.S. Asbestos Personal Injury Trust Fund was created to provide structured, fair compensation to individuals harmed by asbestos exposure from the company's products. It remains a key mechanism for delivering justice to victims of asbestos-related diseases.